Gilead Posts Strong Profit as HIV-Drug Sales Rise Amid Mixed Overall Revenue

Gilead Sciences reported a solid profit for the quarter, driven by strong demand for its HIV treatments including its new prevention drug.

HIV drug sales rose about 4 % to $5.3 billion, aided by early revenues from the injectable prevention medication Yeztugo. However, overall product sales fell 2 % to $7.3 billion because of declines in COVID-19 and cell-therapy treatments.

Total revenue reached $7.77 billion, benefitting from a one-time intellectual-property sale of roughly $400 million. Earnings per share surged to $2.43, well above last year’s $1.00 and ahead of market expectations.

The company raised the lower end of its 2025 earnings forecast to $8.05 per share and nudged up the lower bound for its product-sales target to $28.4 billion. Gilead said it expects the HIV prevention market to grow as more insurers cover Yeztugo.

Despite the bump, analysts caution the earnings beat leaned on non-product revenue and cost control, meaning quality of growth may not be as strong as the headline suggests.

Gilead’s performance underscores how HIV and its prevention market remain critical growth drivers even as other segments face pressures.